托伐普坦治疗小细胞肺癌伴抗利尿激素异常分泌综合征所致的低钠血症  

Tolvaptan against hyponatremia induced by syndrome of inappropriate secretion of antidiuretic hormone in small cell lung cancer patients

作　　者：蒋月强 李瑞超 

机构地区：[1]华中科技大学同济医学院附属同济医院综合医疗科,湖北武汉430030

出　　处：《中国医院药学杂志》2017年第22期2281-2284,共4页Chinese Journal of Hospital Pharmacy

基　　金：同济医院院基金(编号:2201101643)

摘　　要：目的:观察托伐普坦治疗小细胞肺癌伴低钠血症的效果。方法:确诊小细胞肺癌伴抗利尿激素异常分泌综合征患者7例,均予以托伐普坦,每日口服1次:7.5 mg,前3天;15 mg,后4天,于第4天、第8天晨查血钠和体质量,并进行ECOG评分。结果:与治疗前比较,所有患者血钠均恢复正常,ECOG评分亦有显著改善,且体质量呈下降趋势。结论:托伐普坦应成为小细胞肺癌伴抗利尿激素异常分泌综合征所致的低钠血症患者的推荐用药。OBJECHVE To observe the effect of tolvaptan against hyponatremia induced by syndrome of inappropriate secre- tion of antidiuretie hormone （SIADH） in small lung cancer patients. METHODS Seven patients were diagnosed as hyponatrem- ia induced by SIADH with small lung cancer. All of them were treated by tolvaptan daily at the dose of 7. 5 mg in the first 3 days and 15 mg in the next 4 days. The serum sodium, body weight and ECOG score were monitored. RESULTS For all the patients, the concentration of serum sodium was raised to normal level as well as ECOG score decreased. Meanwhile, the tend- ency of weight loss was observed in all the patients. CONCLUSION Tolvaptan should be recommended as a management of hy- ponatremia induced by SIADH in small cell lung cancer patients.

关 键 词：托伐普坦 低钠血症ECOG评分 抗利尿激素异常分泌综合征 小细胞肺癌 

分 类 号：R969[医药卫生—药理学]